Betancourt Nutrition understands that there have been some statements on this forum that either implied or expressly claimed that SI03, Inc., Syntrax, or Derek Cornelius sold Lipokinetix or a fat burner (a) knowing that it was potenitally dangerous or injurious, even lethal, to customers, and (b that after hearing complaints that some people suffered injuries or died from using it, they knowingly ramped up production of Lipokinetix and continued to sell that product. Betancourt Nutrition understands that such statements were made by, among others, an individual using the pseudonym "TMac26."
Betancourt Nutrition never authorized or directed anyone, including "TMac26," to make such statements. To the extent it appeared that such statements were made by anyone acting as a representative for Betancourt Nutrition, Betancourt Nutrition regrets it and apologizes to the members of theis online community, to SI03, Inc., Syntrax, and Derek Cornelius. To the best of Betancourt Nutrition's first-hand knowledge, such statements are not true. Other than this statement, Betancourt Nutrition will make no further comments on this matter.
|
-
08-24-2012, 08:44 AM #1
Betancourt Nutrition Statement on Syntrax
-
08-24-2012, 08:49 AM #2
-
08-24-2012, 08:56 AM #3
-
08-24-2012, 09:00 AM #4
-
-
08-24-2012, 09:09 AM #5
-
08-24-2012, 09:11 AM #6
-
08-24-2012, 09:13 AM #7
-
08-24-2012, 09:17 AM #8
-
-
08-24-2012, 09:28 AM #9
-
08-24-2012, 10:43 AM #10
-
08-24-2012, 10:47 AM #11
-
08-24-2012, 10:49 AM #12
-
-
08-24-2012, 10:50 AM #13
-
08-24-2012, 10:58 AM #14
-
08-24-2012, 11:14 AM #15
-
08-24-2012, 11:16 AM #16
-
-
08-24-2012, 11:23 AM #17
Around 2003 Tetrabol, the designer supplement produced by the American company Syntrax, was doing pretty well. Bodybuilders who took the steroid – which was disguised as a supplement – reported a weight gain of several kilograms and a slight decrease in fat mass. Almost a decade later Anne Bauer and Felicitas Rataj of the German Institute of Doping Analysis and Sports Biochemistry looked into exactly what Tetrabol contained. They discovered that the ingredients were different from the manufacturer's claims…
According to the manufacturer, the active ingredient in Tetrabol was the THP-ether of androst-4-ene-3,17-diol, a testosterone analogue which can be up to 60 percent as effective as testosterone. Androst-4-Ene-3,17-Diol was sold in the US as a pro-hormone until George Bush banned most pro-hormones in 2004.
Like testosterone, androst-4-ene-3,17-diol is not very suitable for oral use. Syntrax solved this problem by attaching a THP-ether to androst-4-ene-3, 17-diol. Animal studies done in the sixties showed that this improves the oral availability of steroid hormones. We don't actually believe this trick works in humans. The human stomach is so acid that THP-ether groups are soon separated from the steroid.
The big problem with labels in the land of supplements is that they are not always correct – and this was the case for Tetrabol too. Tetrabol actually contained a mixture of two compounds (1:1) shown above.
Chemists refer to both these compounds as 17-hydroxyandrosta-3,5-diene-17-THP. The difference between the two compounds is the way in which the ether is attached to the steroid.
Both compounds can attach themselves to the androgen receptor and may have a muscle strengthening effect, the researchers discovered from an in-vitro study they did. For this they used genetically modified yeast cells with an androgen receptor.
When the researchers studied what happens when humans take 17-hydroxyandrosta-3,5-diene-17-TH, they discovered five metabolites in their test subjects' urine. One of these you may be familiar with: 4-hydroxy-androstenedione, which is marketed as the anti-oestrogen Formestane.
Three of the metabolites had an androgenic effect, the researchers discovered. The strongest effect came from 4-OH-androst-4-ene-3,17-dione.
-
08-24-2012, 11:27 AM #18DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service
Food and Drug Administration
Washington, DC
Dear Health Care Professional Colleague:
We are alerting you about a dietary supplement product that we believe presents a serious public health risk. Lipokinetix, distributed by Syntrax Innovations, Inc., has been implicated in several cases of serious liver injury. The Food and Drug Administration (FDA) has received reports of at least six persons who developed acute hepatitis and/or liver failure while using Lipokinetix. The injuries reported to FDA occurred in persons between 20 and 32 years of age. No other cause for liver disease was identified. In all cases, no preexisting medical condition that would predispose the consumer to liver injury was identified. Onset of liver injury was observed between 2 weeks and 3 months of starting Lipokinetix.
Lipokinetix has been promoted for weight loss by ‘mimicking exercise’ and supporting ‘an increased metabolic rate’. The product contains norephedrine (also known as phenylpropanolamine or PPA), caffeine, yohimbine, diiodothyronine, and sodium usniate.
FDA has issued a consumer warning advising consumers to stop using this product and to consult their physician if they are experiencing symptoms possibly associated with this product, particularly nausea, weakness or fatigue, fever, abdominal pain, or any change in skin color.
We urge you to review your cases of hepatitis in order to determine if any may be related to the use of dietary supplements in these patients. Adverse events associated with the use of dietary supplements should be reported as soon as possible to FDA's MedWatch program by telephone (1-800-332-1088) or internet (http://www.fda.gov/medwatch).
Thank you for your efforts and cooperation in addressing this potentially serious public health issue. For additional information, see http://www.cfsan.fda.gov.
Sincerely yours,
Christine Lewis Taylor, Ph.D.
Director
Office of Nutritional Products, Labeling and Dietary Supplements
Center for Food Safety and Applied Nutrition
The FDA is warning consumers to immediately stop use of the product Lipokinetix, marketed as a dietary supplement (for weight loss) by Syntrax Innovations, Inc. FDA has received multiple reports of persons who developed liver injury or liver failure while using Lipokinetix. The product contains norephedrine (also known as phenylpropanolamine or PPA), caffeine, yohimbine, diiodothyronine, and sodium usniate. FDA is also advising consumers to consult their physician if they are experiencing symptoms possibly associated with this product, particularly nausea, weakness or fatigue, fever, abdominal pain, or any change in skin color.
Five patients (four women and one man) were treated at Cedars-Sinai Medical Center, Los Angeles, California, and two patients (both men) were identified through the FDA MedWatch program. All seven patients had taken LipoKinetix according to the manufacturer's recommendations, and none were taking prescription or over-the-counter medications (including acetaminophen). No patient had a medical history, and none were obese. Results of serologic testing for hepatitis A, B, and C were negative in all patients. Results of autoimmune serologic testing (for antinuclear antibodies and anti–smooth-muscle antibodies) and results of testing for cytomegalovirus and Epstein–Barr virus were also negative in five patients who were tested. The five patients from Cedars-Sinai Medical Center were Japanese nationals residing in the Los Angeles area. They had purchased different lot numbers of the product at the same health food store. Symptoms appeared within 4 weeks after initial ingestion of LipoKinetix.
-
08-24-2012, 11:41 AM #19
-
08-24-2012, 05:56 PM #20
-
-
08-25-2012, 04:35 AM #21
-
08-25-2012, 04:39 AM #22
-
08-27-2012, 01:35 PM #23
-
08-28-2012, 07:38 AM #24
-
-
08-28-2012, 08:48 AM #25
-
08-28-2012, 09:15 AM #26
-
08-28-2012, 09:16 AM #27
-
08-28-2012, 09:17 AM #28
-
-
08-28-2012, 09:27 AM #29
He has to as part of their settlement. Reps ran their mouths about Syntrax( and rightfully so IMO) so now the companies they rep have to incur the consequences.
Great, can't wait for a month of bumping this worthless thread.
This is just a feeble attempt to try and shame the companies whose reps referenced Syntrax in a negative manner. The best thing we can do is ignore this thread and not let Syntrax get any of the attention they seek.To miłość nawraca serca i daruje pok�j ludzkości - Jan Paweł II
-
08-28-2012, 09:31 AM #30
- Join Date: Jul 2011
- Location: Germany, Germany, Germany
- Posts: 6,068
- Rep Power: 17811
the other thread was just extremely confusing. very few people had a clue what was going on, yet it was bumped several times a day. kind of defeats the purpose of an official statement if no one has a clue what that statement really means... but I guess they have the right to be illogical if they so desire.
Bookmarks